Somatostatin in the treatment of severe gastrointestinal bleeding from peptic origin. A multicentric controlled trial.

Abstract

Results of a multicentric controlled trial on the efficacy of somatostatin in the treatment of severe gastrointestinal bleeding from peptic origin is reported. The trial was carried out on 90 patients presenting with severe bleeding from hemorrhagic gastric disease in 20 cases, from gastric ulcer in 31 and from duodenal ulcer in 39. Diagnosis was ascertained by endoscopy. Fifty-three patients were treated with somatostatin; in 95% of cases the bleeding was controlled in an average time of 7h 37'. Thirty-seven patients were treated with H2 receptors antagonists and the bleeding was controlled in 76.3% of cases in an average time of 21h. Cases treated with somatostatin required a lower amount of blood transfusion (1 Unit/patient, against 2.7 Units). The better efficacy of somatostatin, at least on a temporary basis, in the control of severe upper gastrointestinal bleeding is underlined while keeping in mind that prevention of recurrence is still an open question.

• Authors: M Basile, S Celi, A Parisi, N Castiglione, S Parisi
• Journal: The Italian journal of surgical sciences (Ital J Surg Sci) Vol. 14 Issue 1 Pg. 31-5 ( 1984) ISSN: 0392-3525 [Print] Italy
• PMID: 6146586 (Publication Type: Clinical Trial, Comparative Study, Journal Article)

Chemical References

• Somatostatin
• Cimetidine
• Ranitidine

Topics

• Acute Disease
• Adolescent
• Adult
• Aged
• Cimetidine (therapeutic use)
• Clinical Trials as Topic
• Duodenal Ulcer (complications, drug therapy)
• Female
• Gastritis (complications, drug therapy)
• Humans
• Male
• Middle Aged
• Peptic Ulcer Hemorrhage (drug therapy)
• Random Allocation
• Ranitidine (therapeutic use)
• Somatostatin (therapeutic use)
• Stomach Ulcer (complications, drug therapy)
• Time Factors